Help us Make a Difference
We’re committed to making a difference in the lives of poor children suffering from neglected infectious diseases. Malaria, diarrheal diseases, and hookworm receive limited investments from the global community. You can help us develop new treatments, train doctors in the field, save lives and alleviate suffering by making a donation to OneWorld Health.
Connect Facebook Twitter Linked InWe take aim at neglected diseases that kill children and other vulnerable populations in the developing world. We work with the pharmaceutical industry, cutting-edge start-ups, university-based research labs, nonprofit hospitals, and organizations in the developing countries to discover, develop, and deliver a blow to these neglected killers.
New medicine for diarrheal disease
We’re fighting cholera and other secretory diarrheas with work on a synthetic drug that provides faster relief of diarrhea symptoms. Combined with the current treatment for infectious diarrheas, this new drug will result in reduced mortality and improved quality of life.
Stable supply of malaria treatment
We are working to develop semisynthetic artemisinin—a key component to artemisinin-based combination therapy, recommended by WHO as a first line treatment for uncomplicated malaria. This affordable, stable, non-seasonal, complementary source of artemisinin will in turn stabilize price volatility, alleviate shortages, and meet future global demand for this lifesaving compound.
Safe, effective, and affordable treatment for kala-azar
In a few short years we’ve developed the antibiotic paromomycin (PMIM) as a safe, effective, and low-cost alternative to previous kala-azar treatments. It has been approved by the government of India, Nepal, and Uganda, and is included on the World Health Organization’s list of Essential Medicines.
Other initiatives
We are working with our partners in India and Vietnam to improve treatment for helminthiasis. We are conducting epidemiological surveys, building capacity, and helping with proper diagnosis. Our Access Team works to ensure that treatments we develop are available and acceptable to at-risk patients.